Objective response rate and progression-free survival as surrogates for overall survival treatment effect: A meta-analysis across diverse tumour groups and contemporary therapies

医学 代理终结点 内科学 随机对照试验 肿瘤科 无进展生存期 恶性肿瘤 总体生存率 黑色素瘤 癌症研究
作者
Adel Shahnam,Nadia Hitchen,Udit Nindra,Sathya Manoharan,Jayesh Desai,Ben Tran,Benjamin Solomon,Stephen J. Luen,Rina Hui,Ashley M. Hopkins,Michael J. Sorich
出处
期刊:European Journal of Cancer [Elsevier BV]
卷期号:198: 113503-113503 被引量:6
标识
DOI:10.1016/j.ejca.2023.113503
摘要

Background Overall survival (OS) results from randomized control trials (RCT) provide the strongest evidence for efficacy of anti-cancer treatments but can take a considerable amount of time to mature. Progression free survival (PFS) and objective response rate (ORR) are used as an early surrogate of OS treatment effect however their validity remains unclear. Our study aims to comprehensively evaluate ORR and PFS as surrogates for OS treatment effect across tumor groups and treatment types. Material and Methods Phase 3 RCTs in solid malignancies that reported OS/PFS and ORR published between 1st of January 2010 and 30th of June 2022 were evaluated. The relationship of surrogate endpoints and OS treatment effect was assessed via weighted linear regression. The coefficient of determination (R2) quantified the fit of the regression model. Results 675 phase 3 RCT comprising of 350 112 patients were analysed. ORR (R2 of 0.10) and PFS (R2 of 0.38) were poor surrogate markers of OS treatment effect. The strength of surrogacy differed within treatment and tumour groups. PFS had the highest R2 for chemotherapy (0.56) and lowest for targeted therapy (0.40). PFS had the highest level of surrogacy for melanoma (R2 = 0.72) and pancreatic cancer (R2 = 0.70) compared to other tumour groups. Importantly ORR and PFS were also poorly correlated to each other (R2 = 0.33). Conclusions ORR and PFS were poor trial-level surrogate markers of OS. The surrogacy performance of ORR and PFS differed by treatment and malignancy sub-type.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
明天过后完成签到,获得积分10
1秒前
jin完成签到,获得积分10
2秒前
yhy完成签到 ,获得积分10
3秒前
黑色卡布奇诺完成签到,获得积分20
3秒前
tanglu发布了新的文献求助10
3秒前
可爱的函函应助梁大海采纳,获得10
3秒前
成就绮琴完成签到 ,获得积分10
4秒前
xicifish完成签到,获得积分10
4秒前
目光之澄完成签到,获得积分10
5秒前
wanci应助研友_ndDPBn采纳,获得10
5秒前
耍酷的白梦完成签到,获得积分10
6秒前
miracle完成签到 ,获得积分10
7秒前
coding完成签到,获得积分10
8秒前
9秒前
犹豫水蓝完成签到,获得积分10
10秒前
yin完成签到,获得积分10
10秒前
JUGG完成签到,获得积分10
10秒前
CipherSage应助阿湫采纳,获得10
11秒前
FIN应助手机采纳,获得20
11秒前
星辰大海应助东黎采纳,获得10
11秒前
量子星尘发布了新的文献求助10
11秒前
wujingshuai完成签到,获得积分10
12秒前
少年完成签到,获得积分10
12秒前
星辰大海应助ficus_min采纳,获得10
13秒前
小柒柒完成签到,获得积分10
14秒前
sdfwsdfsd完成签到,获得积分10
15秒前
亮仔完成签到,获得积分10
16秒前
土豆丝发布了新的文献求助10
16秒前
ylw完成签到,获得积分20
17秒前
西门明雪完成签到,获得积分10
17秒前
17秒前
烟花应助万松辉采纳,获得10
18秒前
爆米花应助不站在雾里采纳,获得10
18秒前
yy完成签到,获得积分20
19秒前
高贵宛海完成签到,获得积分10
19秒前
854fycchjh完成签到,获得积分10
20秒前
21秒前
研友_ndDPBn发布了新的文献求助10
21秒前
番茄发布了新的文献求助30
21秒前
上官若男应助fw20210085采纳,获得10
22秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038524
求助须知:如何正确求助?哪些是违规求助? 3576221
关于积分的说明 11374737
捐赠科研通 3305912
什么是DOI,文献DOI怎么找? 1819354
邀请新用户注册赠送积分活动 892688
科研通“疑难数据库(出版商)”最低求助积分说明 815048